Cervicheck

Anirban Palit and Sayantani Pramanik Palit are Season 3's most mission-critical healthcare founders. The husband-wife duo, along with co-founders Palna Patel and Dr. Bhagirath Modi, founded Pragmatech Healthcare Solutions in 2019 with a singular mission: making cervical cancer screening accessible to every Indian woman by eliminating the barriers (social stigma, discomfort, lack of awareness, limited healthcare access) that prevent 96.9% of Indian women from ever being screened. The founding insight emerged from a devastating healthcare reality: cervical cancer kills over 77,000 Indian women every year, yet the disease is 100% preventable if detected early through regular screening. The reason so few women get screened is not ignorance but structural: traditional screening (Pap smear) requires visiting a hospital, undressing before a clinician, and undergoing an uncomfortable procedure. In a country where social stigma around gynaecological examination is profound, this barrier is ofte

CerviCheck is India's first patent-pending self-sampling cervical cancer screening kit, converting the most invasive and stigmatised cancer screening procedure in Indian women's healthcare (the Pap smear) into a private, painless, self-administered home test. The kit includes a specially designed self-collection device, clear step-by-step instructions, and a pre-paid return envelope for laboratory submission. The product addresses the most fundamental healthcare access paradox in Indian women's health: cervical cancer is the easiest cancer to prevent (screening detects pre-cancerous lesions that can be treated before they become cancerous) yet has one of the lowest screening rates (3.1%) among all cancers because the screening process itself creates the barrier.

Amount Asked: ₹75 lakhs Equity Offered: 1.5% Implied Pre-Money Valuation: ₹50 crore

Anirban and Sayantani opened Season 3 Episode 29 with the most statistically devastating public health pitch of the season: every year, thousands of Indian women die from cervical cancer, a disease that is 100% preventable through early screening, yet only 3.1% of Indian women have ever been tested. The pitch immediately established that CerviCheck was not a consumer product seeking market share but a healthcare intervention seeking to save lives. Sayantani's emotional delivery of the pitch connected every Shark to the personal reality that their mothers, wives, sisters, and daughters face the same screening gap. The product demonstration showed the self-sampling kit's simplicity: no hospital visit required, no clinician involvement, no discomfort, complete privacy.

Aman Gupta raised concerns about the reliability of self-collected samples compared to traditional clinician-collected Pap smears. Vineeta Singh appreciated the mission but exited because the pre-revenue medical device stage was outside her consumer brand investment comfort zone. Amit Jain asked about target market, go-to-market strategy, revenue model, and pricing. Ritesh Agarwal made a competing offer, seeing the potential for scaling the product through his distribution and operations expertise. Namita Thapar was the most strategically aligned Shark. As Emcure Pharmaceuticals' Executive Director, she had the deepest understanding of healthcare product commercialisation, clinical validation pathways, hospital and pharmacy distribution networks, and regulatory compliance in India.

The founders asked ₹75 lakhs for 1.5% equity (₹50 crore valuation). Namita offered ₹75 lakhs for 5% equity (₹15 crore valuation). Ritesh also made a competing offer. The founders chose Namita despite the 3.3x valuation markdown (₹50 crore to ₹15 crore) because her Emcure pharmaceutical ecosystem was the most commercially irreplaceable strategic asset for a healthcare diagnostics company: hospital relationships, pharmacy distribution channels, clinical trial expertise, and regulatory navigation capabilities that no other Shark could provide.

Anirban Palit and Sayantani Pramanik Palit accepted Namita Thapar's offer of ₹75 lakhs for 5% equity at ₹15 crore valuation. The founders chose Namita over Ritesh because Emcure's pharmaceutical distribution network, clinical validation expertise, and women's healthcare product portfolio created the most strategically complete investor alignment for a cervical cancer screening medtech company. The deal was Season 3's most naturally obvious Shark-founder match: India's only pharmaceutical Shark investing in India's only cervical cancer self-screening kit company.

CerviCheck gained significant nationwide attention after its Shark Tank India appearance, but the post-episode journey was complicated by an unexpected controversy. When model Poonam Pandey faked her own death in January 2024 as a "cervical cancer awareness stunt," social media users connected the stunt to CerviCheck's founders, trolling them online. Co-founder Anirban Palit addressed the trolling publicly: "We were called out as 'Poonam Pandey ki company hai.'" The founders defended their position, clarifying that they had no connection to Poonam Pandey's stunt and that their product was a genuine healthcare innovation designed to save lives, not a publicity vehicle. CerviCheck continues its journey toward commercial launch. The product is moving through the clinical validation and regulatory approval process, with Namita's Emcure pharmaceutical expertise providing the specific guidance needed to navigate India's medical device regulatory framework.